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Virtual molecular catalogs have limited utility if member compounds are (i) difficult 
to synthesize or (ii) unlikely to have biological activity. The Distributed Drug 
Discovery (D3) program addresses the synthesis challenge by providing scientists 
with a free virtual D3 catalog of 73,024 easy- to- synthesize N- acyl unnatural α- amino 
acids, their methyl esters, and primary amides. The remaining challenge is to docu-
ment and exploit the bioactivity potential of these compounds. In the current work, a 
search process is described that retrospectively identifies all virtual D3 compounds 
classified as bioactive hits in PubChem- cataloged experimental assays. The results 
provide insight into the broad range of drug- target classes amenable to inhibition 
and/or agonism by D3- accessible molecules. To encourage computer- aided drug dis-
covery centered on these compounds, a publicly available virtual database of D3 
molecules prepared for use with popular computer docking programs is also 
presented.
K E Y W O R D S
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1 |  INTRODUCTION
Virtual compound catalogs[1–4]/libraries[5–9] can be useful 
sources of candidate molecules for drug discovery. However, 
two major factors often limit their utility: (i) Member com-
pounds and analogs may be difficult to synthesize[10] or (ii) 
there is no inherent probability of biological activity. To the 
first issue, we have created large virtual catalogs of N- acyl 
α- amino acids and their methyl ester and primary amide de-
rivatives based on reproducible procedures and demonstrated 
student syntheses of individual catalog members 1[2,4] 2,[3], 
and 3[11] (presented here for the first time, Figure 1).
The purpose of the current work is to address the second 
issue by assessing the existing or potential biological activity 
of these compounds through a chemoinformatics analysis, 
and providing an example of D3- centered computer- aided 
drug discovery. The pharmacological activity of virtual D3 
molecules can be demonstrated in two ways: prospectively 
by synthesizing and testing catalog members in biological 
assays, or retrospectively by searching the literature and other 
databases for previously documented activity (Fig. SI-1).
The prospective approach was first pursued as an initial 
proof of concept (Fig. SI-1, left arrow). A small number of 
D3 compounds 1 were synthesized and submitted to the NIH 
Molecular Libraries Initiative for testing in established high- 
throughput screens,[12] resulting in hits in disparate NIH bio-
assays. Further investigation of one of these hits (CID 971933, 
AID 132162) identified a published analog, also present in 
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2 |   ABRAHAM et Al.
the D3 virtual catalog, with documented biological activity. 
That analog had been key to the development of nateglinide, 
a marketed drug to treat type 2 diabetes mellitus.[13,14]
Inspired by this suggestive finding, a retrospective search 
(Fig. SI-1, right arrow) was undertaken to identify other exam-
ples of virtual catalog members with documented biological 
activity. In this article, we identify all enumerated D3 unnatu-
ral and natural N- acyl α- amino acids (1), N- acyl α- amino acid 
methyl esters (2), and N- acyl α- amino acid amides (3) that are 
listed among the active compounds in the PubChem database 
of >1 million bioassays (AID, Assay ID). By unnatural, we 
mean compounds with D (normally R) stereochemistry and/or 
a non- proteinogenic side chain, versus natural compounds with 
L (normally S) stereochemistry and/or a proteinogenic side 
chain. Members of this list are termed “D3/PubChem actives.” 
The hits from this search give credibility to the prospective 
drug discovery potential of the D3 catalog and suggest areas 
for future discovery research. Within the D3/PubChem actives 
list, relevant PubChem screens that specifically target single 
proteins are also categorized (Fig. SI-2). These protein targets 
then offer the opportunity to construct structure- based compu-
tational models for predictive analysis of D3 virtual catalogs.
In addition to this chemoinformatics analysis, a new 
publicly available database of three- dimensional D3 struc-
tures for use in virtual screening projects, available free of 
charge from http://durrantlab.com/liglib/iupui/d3_docking/ 
(accessed February 27, 2017), is described. To demonstrate 
its utility, this database was used in a virtual screen against 
peptidyl- prolyl cis- trans isomerase NIMA- interacting 1 
(Pin1), a potential target for future cancer chemotherapies.[15] 
This analysis predicted the biological activity of known com-
pounds and suggested molecules with the potential for even 
greater activity. The methodology presented should assist 
others in the field who similarly wish to harness the power of 
enumerated compound catalogs in drug discovery.
2 |  METHODS AND MATERIALS
2.1 | Enumeration protocol
Virtual catalogs of 73,024 unnatural or natural N- acyl α- 
amino acids (1; 24,416 compounds), N- acyl α- amino acid 
esters (2; 24,192 compounds), and N- acyl α- amino acid 
amides (3; 24,416 compounds), called the “D3 N- Acyl α- 
Amino Acid,” “D3 N- Acyl α- Amino Acid Ester,” and “D3 
α- N- Acyl Amino Acid Amide” sets, respectively, were 
enumerated from diversity sets of commercially available 
electrophiles and carboxylic acids (100 members each)[2] 
using CombiChem for Excela or, more recently, ChemAxon,b 
Issues of stereochemistry were addressed in this enumeration 
to yield compounds with two to eight stereoisomers (see Fig. 
SI-4, and associated text for a detailed discussion).
2.2 | PubChem/D3 searching protocol
A series of Boolean substructure searches was used to identify 
all D3- like N- acyl α- amino acid derivatives (4, 5, or 6) and 
N- acyl dipeptide derivatives (7, 8, or 9) present in PubChem 
(i.e., “PC- CID” compounds in Figs. SI-3, SI-4, SI-5, and SI-
6). See the Supporting Information for full Boolean search 
details.
2.3 | Calculating molecular properties
Schrodinger’s Maestro Suitec was used to calculate the chem-
ical properties of the compounds in the D3 N- Acyl α- Amino 
Acid set, NCI Diversity Set III,[16] and ChemBridge Diversity 
CombiSet[17,18] libraries, which contain 24,416, 1,597, and 
30,000 compounds, respectively. One electrically neutral, 
three- dimensional structure of each compound was created 
using Schrodinger’s LigPrep module,d as required to calcu-
late molecular properties. Molecular geometries were opti-
mized using the OPLS_2005 force field,[19] hydrogen atoms 
were added or removed as required to achieve electrical neu-
trality (e.g., carboxylates were protonated, protonated amines 
were deprotonated, etc.), salts were removed, only the most 
probable tautomer was considered, and one low- energy con-
formation was generated for each ring. The D3 input files ex-
plicitly specify the stereochemistry at each chiral center; for 
compounds from other virtual catalogs that lack specified chi-
ralities, a single chiral molecule was created per input struc-
ture, chosen from among the many possible enantiomers that 
could have been enumerated. Once these 3D structures had 
been created, Schrodinger’s QikProp modulee was used to 
calculate the molecular weight, predicted LogP, and number 
of hydrogen- bond donors and acceptors for each compound.
Occasionally, the Schrodinger software was unable to 
process a given molecule. In the end, molecular properties 
were generated for 92%, 96%, and 99% of the D3 N- Acyl α- 
Amino Acid Set, the NCI Diversity Set III, and ChemBridge 
Diversity CombiSet libraries, respectively. The relevant fig-
ures and statistics were generated using these compounds.
F I G U R E  1  Generic structures of 
the 73,024 unnatural and natural N- acyl 
α- amino acid derivatives in the D3 virtual 
catalog
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2.4 | Preparing a virtual catalog of three- 
dimensional D3 structures for docking
Schrodinger’s LigPrep module was used to generate 3D struc-
tures of all D3 compounds for use in docking studies. Unlike 
the virtual library of 3D compounds generated to calculate 
molecular properties, the docking library should account for 
the multiple ionic, tautomeric, and conformational states po-
tentially associated with each compound under physiological 
conditions. To this end, Schrodinger’s Epik algorithm[20,21] 
was used to determine all protonation states at pH values 
ranging from 5.0 to 9.0. All tautomers were enumerated, and 
one low- energy ring conformation was considered per com-
pound. After salt molecules had been removed, the 3D geom-
etry of each compound was optimized using the OPLS_2005 
force field.[19] The chiralities explicitly specified in the D3 
database were retained. When alternate protonation and tau-
tomeric states were considered, there were ultimately 27,220, 
26,794, and 27,036 N- acyl α- amino acid (1), N- acyl α- amino 
acid ester (2), and N- acyl α- amino acid amide (3) derivatives, 
respectively. These structures were saved in the SDF format, 
which is compatible with computer docking programs like 
Schrodinger’s Glide.[22,23]
To facilitate docking with programs such as AutoDock[24] 
and VinA,[25] each of the structures was also saved in the 
PDBQT format. The SDF to PDB conversions were per-
formed using open BABel.[26] The PDB to PDBQT conver-
sions, which involved computing Gasteiger partial charges 
for each atom,[27] assigning AutoDock atom types, and merg-
ing non- polar hydrogen atoms with their parent heteroatoms, 
were performed using AutoDocktools.[24] Compound tor-
sions were assigned using AutoDock’s AutoTors utility to 
allow full molecular flexibility during docking.
2.5 | Benchmark virtual screen
AutoDock Vina was used to dock the entire 24,416- member 
D3 N- acyl α- amino acid set into the 3KAI Pin1 structure.[28] 
The ligand PDBQT files were taken from the database 
 described in the previous paragraph. The protein was pro-
cessed using Schrödinger’s Protein Preparation Wizard[29] 
to add hydrogen atoms, optimize hydrogen- bond networks, 
relax the structure, etc. The processed structure was then 
converted to the PDBQT format using AutoDocktools.[24] 
Compounds were docked into a cube (20 Å × 20 Å × 20 Å) 
centered on the Pin1 active site, using the Rocce cluster pro-
vided by the National Biomedical Computation Resource. 
Default Vina parameters were used.
2.6 | Combinatorial chemistry and the 
D3 initiative
In theory, the number of drug- like compounds exceeds 
1060.[30] Any hope of exploring all of “drug space,” whether 
by computational or experimental means, must be abandoned 
from the outset. Given that researchers are restricted to a lim-
ited subspace, it is prudent to focus on small molecules that 
can be readily synthesized using simple and robust synthetic 
procedures.[1] These requirements can be met by design-
ing drug discovery projects around readily accessible small 
molecules derived using carefully designed synthetic meth-
odologies. Enumerated virtual combinatorial catalogs can 
potentially include far more compounds than even the largest 
preexisting physical collections used in traditional screening, 
and subsequent drug optimization is simpler because analogs 
of any initial hits can often be easily prepared using the same 
chemistry.
In this spirit, a subset of the chemistry employed in the 
D3 initiative focuses on chemical reactions that produce 
unnatural and natural N- acyl α- amino acids (1),[2,4,31,32] 
 N- acyl α- amino acid esters (2),[3] and N- acyl α- amino acid 
amides (3),[11] as well as their dipeptide counterparts. These 
compounds are derived from combinatorial scaffolds 1–3 
(Scheme 1) with “sites of diversity” to which new chemical 
groups can be added (e.g., new α- side chains, N- terminal sub-
stituents, and/or various carboxylic acid derivatives: –CO2H, 
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members 1, 2, and 3
N
O
Ph
Ph
N
O
Ph
Ph R1
H
N
O
OMe
R1O
R2
H3N
O
R1Base
TFA (X=O or NH)
Coupling
Step 4
N-Acylation
5 6
2
4 (X=O or NH)
R1-X
XXX
Step 5
Cleavage
Step 1
Alkylation
Step 2
Hydrolysis
Cl
H2N
O
R1
7
X
H
N
O
R1O
R2
8
X
Step 3: 
NeutralizationBase
1N HCl
R2CO2H
H
N
O
OH
R1O
R2
1
H
N
O
NH2
R1O
R2
3
or
MeOH/Base
(X=O)
5
CO
LO
U
R 
on
lin
e,
 B
&W
 in
 p
ri
nt
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
4 |   ABRAHAM et Al.
–CO2Me, and –CONH2). The simple solid- phase reactions 
employed in D3 can also be readily adapted to an educational 
setting with undergraduate or graduate students.[1–4]
The synthetic chemistry for the five- step preparation of 
D3- catalog compounds 1,[2,4] 2,[3] and 3[11] is outlined below 
(Scheme 1). The starting benzophenone imine (Schiff base) 
of glycine bound to either Wang (X=O) or Rink (X=NH) 
resin (4) is deprotonated with base. The intermediate car-
banion then reacts with an alkyl halide or Michael acceptor 
(both represented as the generic red electrophile R1X) to 
form racemic 5, which contains the first variable input, an R1 
group. Hydrolysis to salt 6 is followed by neutralization to the 
free amine 7. The second variable input, R2 in blue, is then 
added with an N- acylation by coupling 7 with a carboxylic 
acid R2CO2H to give 8 (when an N- acyl or other protected 
α- amino acid is used as the acylating agent R2CO2H, and the 
D3 products are protected dipeptide derivatives). Finally, 
the resin- bound product is cleaved from the resin to yield an 
unnatural N- acyl α- amino acid 1 (using trifluoroacetic acid, 
TFA), an unnatural N- acyl methyl ester 2 (MeOH/base) from 
Wang resin, or an unnatural N- acyl primary amide 3 from 
Rink amide resin (TFA).
This protocol produces a racemic mixture of both (S)- and 
(R)- N- acyl α- amino acid derivatives, allowing both epimers 
to be simultaneously tested in any biological assay. When ac-
tivity is detected, an optically enriched sample of the mixture 
can be produced by enantioselective solution- or solid- phase 
synthesis,[31,32] or chiral chromatography.[33,34]
A virtual catalog of 73,024 synthesizable compounds 
accessible by D3 solid- phase reaction sequences was enu-
merated from a diversity set of 100 and 100 commercially 
available electrophiles and carboxylic acids, respectively.[2] 
This catalog contains 12,208 each of the (S)- and (R)- N- 
acyl α- amino acids 1; 12,096 each of the (S)- and (R)- N- 
acyl α- amino acid methyl esters 2; and 12,208 each of the 
(S)- and (R)- N- acyl α- amino acid primary amides 3. See the 
Supporting Information (pp. SI- 4 & SI- 5) for a more complete 
explanation of the chemical enumeration and library sizes.
3 |  RESULTS AND DISCUSSION
3.1 | α- Amino acid derivatives and 
biological activity
Many endogenous α- amino acids have known biologi-
cal effects beyond the fundamental role they play as 
protein- building blocks. As D3 compounds are based on 
the α- amino acid scaffold, it is reasonable to suppose that 
they may be enriched with bioactive compounds. A col-
lection of 40 approved drugs containing the α- amino acid 
structural framework (nitrogen to alpha- carbon to car-
bonyl unit, highlighted in red), is shown in Table SI-1 (see 
Supporting Information for full structures, references, and 
other data). Of these compounds, 35% (14/40) are N- acyl 
α- amino acids, N- acyl dipeptides, or their ester or amide 
derivatives: alvimopan, bortezomib, ceftaroline, dorip-
enem, folic acid, lacosamide, lenalidomide, methotrexate, 
pemetrexed, penicillin V, pralatrexate, raltitrexed, tacroli-
mus, and valsartan.
3.2 | Identifying known drug targets of 
D3 compounds
To verify the pharmacological utility of the D3 libraries, we 
explored whether or not any virtual D3 molecules had previ-
ously reported biological activity. Among the >51 million 
molecules with unique chemical structures (CIDs) deposited 
in the PubChem database (Fig. SI-2),[35] approximately 3,000 
compounds were also serendipitously present in D3 cata-
logs (Figure 2a). These molecules included 76 compounds 
(Figure 2b) that were active in 95 different PubChem bioas-
says (AIDs).
Many PubChem assays detect phenotypic responses or 
changes to entire biochemical pathways. These types of 
screens are useful for drug discovery, but structure- based 
drug design (“SBDD,” e.g., computer docking) requires a 
specific macromolecular target. By manually examining 
the PubChem assay descriptions of the 95 assays noted 
above, we identified 45 that are likely to involve binding 
to the orthosteric pockets[36] of 32 distinct single- protein 
drug targets (Table SI-2). Given that D3 compounds are 
α- amino acid derivatives, the majority of these protein 
targets (25 of 32) had endogenous or natural substrates 
that were free α- amino acids, short peptides, specific pro-
tein residues, or α- amino acid metabolites. However, tar-
gets with nucleic acid and steroidal endogenous ligands 
are also amenable to D3 binding, suggesting even broader 
utility.
Given that so many of these drug targets bind to natu-
ral  α- amino acids, it is not surprising that there are many 
 N- acyl α- amino acids with natural side chains among the 
D3/PubChem actives. The strength of the D3 protocol lies 
F I G U R E  2  The chemoinformatics 
analysis. Common D3 virtual and bioactive 
PubChem compounds
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in its ability to produce combinatorially diverse sets of both 
 unnatural and natural α- amino acid derivatives. The 45 
SBDD- amenable PubChem assays contained 54 unique D3 
active compounds (Figures 2c, 3; Table SI-3). Insight into the 
structural features governing the activity of these 54 com-
pounds is provided in the section entitled “Comparing the D3 
virtual catalog members with D3/PubChem actives,” below.
3.3 | A computer- aided drug discovery 
example: Pin1 inhibitors
To further demonstrate the utility of the D3 virtual database, 
attention was next focused on PubChem SBDD- amenable 
assays that include active compounds also present in D3 
catalogs. One of these was a PubChem assay against Pin1 
F I G U R E  3  Fifty- four D3/PubChem hits in SBDD- amenable assays (i.e., assays judged likely to involve binding to orthosteric pockets of 
single- protein targets). See Table SI-3 for further details
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reported in 2010 (AID: 474989, Table SI-2, entry 14). Also 
known as “peptidyl- prolyl cis- trans isomerase (PPIase) 
NIMA- interacting 1,” Pin1 catalyzes the cis- trans isomeri-
zation of prolyl amide bonds in select substrate proteins. 
Because it is thought to play a role in cancer pathogenesis, 
Pin1 has been studied as a potential drug target for novel can-
cer chemotherapies. The PubChem assay AID 474989 de-
tected specific binding (leading to inhibition) to the primary 
Pin1 active site[15] and reported compounds that have a Ki 
less than 50 μM.
Thirteen of the 32 molecules tested for Pin1 activity in 
2010[15] had been previously disclosed in the 2008 virtual D3 
N- acyl α- amino acid set.[2] Of these thirteen compounds, ten 
were reported as active in PubChem (Ki < 50 μM), and three 
with lower affinities were reported as inactive. Twelve of the 
13 D3 compounds were monosubstituted N- acyl phenylala-
nines (63, G = H, 2- or 3- F, 2- or 3- or 4- CF3, 2- or 3- or 4- 
CN, 3- or 4- Me, 3- Cl), and one was a phenylalanine vinylog 
42 (Figure 4).
It is notable that these Pin1 inhibitors have the (R)- or 
D- stereochemistry not normally present in proteinogenic α- 
amino acids and their derivatives. This highlights a strength 
of the D3 approach. D3- based chemistry enables the synthe-
sis and testing of both α- amino acid stereochemistries (usu-
ally in the racemic form, and then separately after racemic 
activity is observed). In contrast, medicinal chemistry is often 
biased in favor of α- amino acids (and their derivatives) with 
the naturally occurring stereochemistry, perhaps due to avail-
ability of starting materials. Without access to the unnatural 
stereoisomer, important drugs or drug leads could be missed. 
Examples of drugs that are unnatural α- amino acids or their 
derivatives include nateglinide,[13] lacosamide,[37] penicilla-
mine,[38] penicillin V,[39] and ximelagatran[40] (see Table SI-1 
and the Supporting Information text for more examples).
To further demonstrate the utility of the D3 catalogs, D3- 
compound binding to Pin1 was evaluated in an in silico bench-
mark screen. A crystal structure of Pin1 (PDB ID: 3KAI) was 
used for docking.[28] To validate this target, the co- crystalized 
compound 64 (Figure 5) was removed from the 3KAI pocket, 
and a known inhibitor and member of the D3 virtual catalog 
(42, Figures 3 and 4, Table SI-3) was docked using AutoDock 
Vina.[25]
The resulting docked pose of bound 42 (Figure 6) closely 
approximated the crystallographic pose captured in the 3JYJ 
Pin1 structure.[15] Given that AutoDock VinA was able to 
reproduce the experimental pose, the entire 24,416- member 
D3 N- acyl α- amino acid set (including the identified Pin1 in-
hibitors) was next docked into 3KAI. As the co- crystallized 
compound 64 was not present in the D3 database, the re-
sults of the virtual screen were not biased in favor of any D3 
compound.
This benchmark virtual screen was particularly adept 
at predicting the activity of the ten known Pin1 inhibitors 
present in the 24,000- member D3 virtual catalog of N- 
acyl α- amino acids (1, Table 1). Six of the ten compounds 
listed as active in PubChem were contained in the top 5% 
(roughly 1,200) of Vina- ranked D3 compounds. A receiver- 
operating characteristic (ROC) curve was next generated, 
with the known inhibitors and remaining compounds serv-
ing as the true positives and negatives, respectively. The 
area under this curve was 0.93, suggesting that, given a ran-
domly selected pair of compounds comprised of one known 
inhibitor and one uncharacterized compound, there is a 93% 
chance that the known inhibitor has the better VinA score.[25] 
Random ranking would put this probability at only 50%.
Given the performance of this virtual screen, some top- 
ranking but untested D3 compounds are also likely Pin1 
F I G U R E  4  Known Pin1 inhibitors[15] present in the D3 N- acyl 
α- amino acid set[2]
H
N
O
O
OH
H
N
O
O
OH
G
63 42
F I G U R E  5  The co- crystallized compound removed from the 
3KAI Pin1 structure prior to docking
H
N
O
O
OH
64
NN
Me
F I G U R E  6  A comparison of the docked and crystallographic 
poses of 42 (CID 45100499, a known Pin1 inhibitor and also a member 
of the D3 virtual database). The docked and crystallographic poses 
are shown in white and yellow, respectively. The compound was 
docked into the 3KAI structure.[28] The actual crystallographic pose 
was taken from the 3JYJ structure[15]
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inhibitors. Although it is beyond the scope of this paper, 
future directions include experimentally synthesizing and 
testing a number of these top- ranked compounds to identify 
small molecules with improved activity.
3.4 | Comparing the D3 virtual catalog 
members with D3/PubChem actives
We next compared the structural characteristics of the 
73,024- member D3 virtual catalog with the 54- member D3/
PubChem active set (Figure 7). These two sets both con-
tain all three D3 structural classes [N- acyl α- amino acids 
(1) and their methyl ester (2) and amide (3) derivatives], 
but in differing proportions. In the larger D3 set (Figure 7, 
left column), the numbers of compounds in each class are 
nearly equal because the D3 molecules were derived com-
binatorially from the same set of 100 electrophile (R1X) 
and 100 carboxylic acid (R2CO2H) inputs, differing only 
in the method of resin cleavage (Scheme 1). The varying 
numbers of 2 are a result of the different cleavage condition 
used, which caused different side chain side reactions. For 
example, if R1 in compounds 1–3 is CH2CO2tBu, cleavage 
of 1 or 3 with TFA converts the protected t- butyl ester to 
the carboxylic acid (CH2CO2tBu → CH2CO2H). In contrast, 
cleavage of 2 with Et3N leaves the side chain unchanged 
(CH2CO2tBu → CH2CO2tBu).
As might be expected, the proportions of structural classes 
in the D3 virtual catalog set are quite different from the D3/
PubChem active set (Figure 7, right column). A lower per-
centage of a particular structural class in the active set could 
imply that it is not fertile territory for drug discovery and 
is overrepresented in the D3 virtual catalog. On the other 
hand, perhaps that structural class is simply underrepresented 
among the PubChem molecules made and tested. Without 
going through a complete analysis of the structural classes 
present in PubChem, both tested and untested, we are con-
fident that this latter hypothesis is the case, especially when 
comparing the structural categories of “proteinogenic/non- 
proteinogenic side chains” and “natural/unnatural side chain 
stereochemistry.” The introduction, via a racemic alkylation 
reaction, of side chains usually not found in proteinogenic 
amino acids is at the core of D3 chemistry. This process 
gives rise to many unnatural side chain residues with equal 
proportions of the natural (e.g. L- or S- ) and unnatural D- 
or R- stereoisomers. To account for the presence, potential 
activity, and computational accessibility of all enantiomers, 
each is explicitly enumerated in the D3 virtual catalog. In 
cases where D3 compounds contain two or three stereogenic 
centers, all four or eight stereoisomers, respectively, are in-
cluded in the catalog.
The preponderance of the natural stereochemistry and side 
chains in the PubChem active set is not surprising given that 
amino acid- based compounds submitted to PubChem for test-
ing are likely biased in favor of derivatives of the more read-
ily available natural (l)- α- amino acid stereoisomer. What is 
noteworthy is the significant number of D3/PubChem active 
compounds (20%) with the unnatural (D)- stereochemistry. 
These would not have been present in the D3/PubChem 
intersection if the D3 project had considered only enantio-
merically pure molecules with the (L)- stereochemistry. The 
observed activity of some racemic PubChem actives (39%) 
may also be explained in part by the D3 methodology, which 
generates the unnatural and natural stereoisomers in equal 
T A B L E  1  The Vina scores and percentile rankings of the ten 
positive controls (i.e., known inhibitors) included in the benchmark 
Pin1 screen
ID Vina score Percentile rank
  
(R)-52 (DDD- 000012382)
−7.3 1.5
  
(R)-51 (DDD- 000012386)
−7.3 1.5
  
(R)-49 (DDD- 000012361)
−7.2 2.4
  
(R)-53 (DDD- 000012365)
−7.2 2.4
  
(R)-50 (DDD- 000012379)
−7.2 2.4
  
(R)-48 (DDD- 000012394)
−7.2 2.4
  
(R)-55 (DDD- 000012383)
−6.9 7.5
  
(R)-47 (DDD- 000012350)
−6.8 10.5
  
(R)-56 (DDD- 000012380)
−6.8 10.5
  
(R)-54 (DDD- 000012387)
−6.6 18.8
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proportions. In any case, the presence of these “unnatural” 
amino acid derivatives in both the D3 virtual catalog and 
PubChem active set demonstrates the value of the D3 virtual 
catalog as a resource for identifying biologically active com-
pounds from an underrepresented structural class.
Finally, when an N- acyl or other protected α- amino acid 
is used as the acylating agent R2CO2H, the D3 products are 
protected dipeptide derivatives (see Fig. SI-5 and associated 
text). In total, such dipeptide derivatives comprise 17% of 
the 73K D3 virtual catalog and 24% of the 54- member D3/
PubChem set (Figures 3 and 7), pointing to the ready avail-
ability of such derivatives via the D3 methodology.
3.5 | The D3 N- acyl α- amino acid 
virtual catalog
The Pin1 virtual screen of the above 24,416- member “D3 
 N- Acyl α- Amino Acid set” illustrates how the D3 chemical 
library can be particularly useful for drug discovery projects. 
Computed chemical descriptors suggest that the compounds 
in this catalog are chemically similar to those of other libraries 
commonly used in virtual and experimental screens (Figure 8). 
For comparison, consider the NCI Diversity Set III (NCI III) 
and the ChemBridge Diversity CombiSet (ChemBridge). The 
average calculated molecular properties of the D3 N- acyl 
α- amino acid set are intermediate between those of these 
two popular libraries, with the exception of the hydrogen- 
bond- donor count, where the ChemBridge set is anomalous 
(Table 2, Figure 7). The overwhelming majority of the catalog 
compounds (97.2%, 98.6%, and 99.8% of the D3 N- Acyl α- 
Amino Acid, NCI III, and ChemBridge compounds, respec-
tively) satisfy Lipinski’s “Rule of Five” for druglikeness.[41]
To encourage broad use of the D3 virtual catalog, struc-
tures of the D3 N- acyl α- amino acids, N- acyl α- amino acid 
esters, and N- acyl α- amino acid amides have been pre-
pared in formats that are compatible with several computer 
docking programs, including AutoDock,[24] Vina,[25] and 
Schrodinger’s Glide.[22,23] Various possible tautomeric, pro-
tonation, and ring conformational states of each compound 
were carefully considered. These virtual catalogs may be 
downloaded free of charge from http://durrantlab.com/liglib/
iupui/d3_docking/ (accessed February 27, 2017).
Many researchers may wish to prepare D3 structures ac-
cording to their own protocols. The SMILES string of each 
D3 compound has also been published on both the D3 (http://
durrantlab.com/liglib/iupui/d3_docking/, accessed February 
27, 2017) and Collaborative Drug Discovery (CDD) (https://
www.collaborativedrug.com, accessed February 27, 2017) 
websites.[42,43] CDD also allows researchers to search and 
download subsets of the entire D3 virtual catalog.
4 |  CONCLUSIONS
Two complementary strengths of D3 virtual catalogs are their 
bioactivity potential and synthetic accessibility. By demon-
strating the retrospective and prospective biological utility 
of these catalogs, this manuscript encourages computational 
chemists to probe D3 molecules with their own tools and hy-
potheses. Compounds enumerated in the virtual catalog are 
based on well- documented D3 procedures, so synthesizing 
and testing computationally selected molecules are entirely 
feasible. The D3 catalogs thus enable collaborations between 
computationalists, synthetic chemists, and biologists.
In summary, to demonstrate the utility of the D3 virtual 
catalog, we identified a number of D3 molecules with known 
biological activity that were present in the PubChem database. 
These results will help guide future drug discovery efforts. 
Using computational techniques such as docking, students, 
and researchers can identify analogs of known modulators 
that are likely to bind to the same target. These compounds 
can then be synthesized and distributed to collaborators, 
F I G U R E  7  Comparing the 73,024 D3 
compounds and the 54 D3/PubChem actives
73K-Member D3 Virtual Catalog of N-Acyl Amino
Acids and Derivatives
54 D3/PubChem Active N-Acyl Amino Acids and 
Derivatives
N-Acyl Amino Acids & Derivatives (73,024 Total) N-Acyl Amino Acids & Derivatives (54 Total)
24,416 N-Acyl Amino Acids (1) (33%) 43 N-Acyl Amino Acids (1) (80%)
24,192 N-Acyl Amino Acid Me Esters (2) (33%) 6 N-Acyl Amino Acid Me Esters (2) (11%)
24,416 N-Acyl Amino Acid Amides (3) (33%) 5 N-Acyl Amino Acid Amides (3) (9%)
R1Xs Yielding Side Chain Types (100 Total) Side Chain Types (54 Total)
13 Proteinogenic Side Chains (13%) 42 Proteinogenic (78%)
Ala (1), Asp (3), Glu (2), Ile (1), Leu (1), Ala (7), Asp (0), Glu (2), Ile (0), Leu (6),
Phe (1), Trp (1), Tyr (2), Val (1) Phe (12), Trp (7), Tyr (3), Val (5)
87 Non-proteinogenic Side Chains (87%) 12 Non-proteinogenic Side Chains (22%)
40 Substituted PhCH
2
X (46%) 10 Unnatural Ring-Substituted Phe (83%)
5 HetCH
2
X (6%) 2 Unnatural Alkyls (17%)
5 Polycyclic ArCH
2
X (6%) Stereochemistry (54 Total)
8 Allylic or Propargylic Halides (9%) 22 Natural (L) Side Chains (41%)
15 Alkyl Halides (17%) 11 Unnatural (D) Side Chains (20%)
14 Michael Acceptors (16%) 21 Racemic (D,L) Side Chains (39%)
N-Acyl Amino Acids vs. Dipeptides (100 Total) N-Acyl Amino Acids vs. Dipeptides (54Total)
83 N-Acyl Amino Acids (83%) 41 N-Acyl Amino Acids (76%)
17 N-Protected Dipeptides (17%) 13 N-Protected Dipeptides (24%)
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who evaluate the pharmacological, enzymatic, or signaling 
effect to confirm or refute the computational predictions. 
Others who wish to identify additional D3 drug targets via 
virtual screening can download a carefully prepared catalog 
of D3 compounds from http://durrantlab.com/liglib/iupui/
d3_docking/.
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The Distributed Drug Discovery (D3) program provides scientists with a free virtual catalog of 73,024 easy- to- synthesize 
N- acyl unnatural α- amino acids, their methyl esters, and primary amides. In the current work, we identify all virtual D3 com-
pounds classified as bioactive hits in PubChem- cataloged experimental assays. The results (i) provide insight into the broad 
range of drug- target classes amenable to modulation by D3- accessible molecules and (ii) suggest future avenues for virtual 
screening/drug discovery projects.
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